Results 51 to 60 of about 10,168 (235)

Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance

Experimental and Molecular Medicine, 2018
Cancer immunotherapy: Boosting anti-tumor immunity New immunotherapies for cancer known as immune checkpoint blockers (ICBs) may help treat many tumor types.
Young-Jun Park, Da-Sol Kuen, Yeonseok Chung   +2 more
doaj   +1 more source

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker [PDF]

Cancer Medicine, 2020
AbstractImmunocheckpoint proteins of tumor infiltrating lymphocytes play an important role in tumor prognosis in the course of tumor clinicopathology. PD‐1 (Programmed cell death protein 1) is an important immunosuppressive molecule. By binding to PD‐L1 (programmed cell death‐ligand 1), it blocks TCR and its costimulus signal transduction, inhibits the
Zhengyi Wang, Xiaoying Wu
openaire   +3 more sources

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Identification of a Ferroptosis-Related Long Noncoding RNA Prognostic Signature and Its Predictive Ability to Immunotherapy in Hepatocellular Carcinoma

Frontiers in Genetics, 2021
Background: Immune checkpoint blockers (ICBs) are increasingly being used to treat patients with advanced hepatocellular carcinoma (HCC), but only a third of these patients are sensitive to ICBs.
Liang Wang, Liang Wang, Xiangwei Ge, Zifeng Zhang, Yating Ye, Ziyi Zhou, Manhong Li, Hongxiang Yan, Lei Wu, Qian Bai, Jipeng Li, Jun Zhu, Jun Zhu, Yusheng Wang   +13 more
doaj   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

TREX1 dictates the immune fate of irradiated cancer cells

OncoImmunology, 2017
The optimal radiation dose and fractionation to induce anti-tumor immunity remain elusive. We recently found that the exonuclease TREX1 abrogates the immunogenicity of irradiated cancer cells by degrading interferon-stimulatory cytosolic dsDNA.
Claire Vanpouille-Box, Silvia C. Formenti, Sandra Demaria   +2 more
doaj   +1 more source

A CASE OF ACUTE CARDIOMYOPATHY DUE TO IMMUNE CHECKPOINT BLOCKER PEMBROLIZUMAB

Journal of the American College of Cardiology, 2020
The use of immune checkpoint inhibitors (ICI) in management of many cancers has increased recently, given their exceptional efficacy in ensuring remission. However, their inflammatory side effects have been associated with cardio-toxicity A 71-year-old man with metastatic renal cell carcinoma (
Raghavendra Makam, Youssef Rahban, David Gerson, Glenn Stokken   +3 more
openaire   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction

Cancer Medicine, 2019
Immune checkpoint blockade (ICB) represents a promising approach in cancer therapy. Owing to the peculiar biologic mechanisms of anticancer activity, checkpoint blockers are accompanied with distinctive response patterns and toxicity profiles.
Hong Wei, Hanyu Jiang, Bin Song
doaj   +1 more source

Firing up the cold tumors by targeting Vps34

OncoImmunology, 2020
Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration.
Bassam Janji, Meriem Hasmim, Santiago Parpal, Guy Berchem, Muhammad Zaeem Noman   +4 more
doaj   +1 more source